Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
AOD-9604 is not FDA-approved for weight loss
For small amounts of delicate drugs, a subcutaneous injection can be a useful, safe, and convenient method of getting a medication into your body
However, because AOD-9604 does not affect appetite or insulin sensitivity, having breakfast immediately after administration does not appear to interfere with the peptides fat tissue effects, making timing more flexible than with compounds that rely on specific insulin or glucose states
By inhibiting it, AOD 9604 reduces your body's ability to create new fat from excess calories
AOD-9604 vs GLP-1 S GLP-1 S (semaglutide) works through an entirely different system than AOD-9604: it activates GLP-1 receptors to slow gastric emptying, increase satiety, and improve glycemic control, producing weight loss primarily by reducing food intake rather than by acting on fat cells directly
For example, in tendon fibroblast cells, BPC-157 dramatically increases phosphorylation (activation) of FAK and paxillin, leading to more cell migration and survival at injury sites
US$ 23.08
US$ 28.68
US$ 25.25
US$ 24.77
